Annex 4:
e) (…) Adopt evidence-informed country-based strategies to improve patient access to affordable medicines (for example, by including relevant medicines in national essential medicines lists, separating prescribing and dispensing, controlling wholesale and retail mark-ups through regressive mark-up schemes, and exempting medicines required for essential noncommunicable disease interventions from import and other forms of tax, where appropriate, within the national context). Promote procurement and use of safe, quality, efficacious and affordable medicines, including generics, for prevention and control of noncommunicable diseases, including access to medicines for alleviation of pain for palliative care and vaccinations against infection-associated cancers, through measures including quality assurance of medical products, preferential or accelerated registration procedures, generic substitution, preferential use of the international non-proprietary names, financial incentives where appropriate and education of prescribers and consumers.